Canagliflozin: a novel treatment option for type 2 diabetes.
Canagliflozin: a novel treatment option for type 2 diabetes.
复制标题
DOI：
10.2147/dddt.s48937
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Taylor JR
中科院分区：
文献类型：
--
作者：
Dietrich E;Powell J;Taylor JR
2型糖尿病仍然是一种具有挑战性的疾病。添加具有正风险-收益比的新药物可能潜在地帮助临床医生和患者实现充分的糖尿病控制。Canagliflzin是目前市场上第一种钠-葡萄糖协同转运体2抑制剂，它提供了一种独特的作用机制：它抑制肾脏对葡萄糖的重吸收，从而增加尿糖排泄。它可以降低大约0.37%-1.16%的血红蛋白A1c；它还可以减轻患者的体重和收缩压，并具有较低的低血糖风险。不良影响包括增加尿路感染和生殖器真菌感染的风险。在这篇手稿中，我们回顾了Canagliflazin及其在2型糖尿病治疗中的潜在作用。
Type 2 diabetes continues to be a challenging disease to manage. The addition of new agents with a positive risk–benefit ratio could potentially assist clinicians and patients in achieving adequate diabetes control. Canagliflozin, the first sodium-glucose cotransporter 2 inhibitor presently available on the market, offers a unique mechanism of action: it inhibits renal reabsorption of glucose, thereby increasing urinary glucose excretion. It reduces hemoglobin A1c by approximately 0.37%–1.16%; it also reduces the patient’s weight and systolic blood pressure and has a low risk for hypoglycemia. Adverse effects include an increased risk of urinary tract infections and genital mycotic infections. In this manuscript we review canagliflozin and its potential role in management of type 2 diabetes mellitus.